According to a candidate gene-based approach, genes involved in pharmacokinetics/pharmacodynamics (PK/PD) of drugs used in DLBCL or genes associated with the immune function were found to be associated with R-CHOP efficacy [31,32]. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.